LUPIN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,578 INR | -1.48% |
|
-3.31% | +19.24% |
| 11:32am | India's pharma export sales to grow faster this year, trade body says | RE |
| May. 27 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,601
INR
Average target price
1,581
INR
Spread / Average Target
-1.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.24% | 8.76B | |
| +40.42% | 731B | |
| +31.34% | 586B | |
| -7.35% | 348B | |
| +17.07% | 319B | |
| +0.50% | 273B | |
| +13.47% | 235B | |
| -6.63% | 203B | |
| +7.49% | 202B | |
| +5.04% | 159B |
- Stock Market
- Equities
- 500257 Stock
- News Lupin Limited
- Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold
